The current state of GPCR‐based drug discovery to treat metabolic disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
One approach of modern drug discovery is to identify agents that enhance or diminish signal transduction cascades in various cell types and tissues by modulating the activity of GPCRs. This strategy has resulted in the development of new medicines to treat many conditions, including cardiovascular disease, psychiatric disorders, HIV/AIDS, certain forms of cancer and Type 2 diabetes mellitus (T2DM). These successes justify further pursuit of GPCRs as disease targets and provide key learning that should help guide identifying future therapeutic agents. This report reviews the current landscape of GPCR drug discovery with emphasis on efforts aimed at developing new molecules for treating T2DM and obesity. We analyse historical efforts to generate GPCR‐based drugs to treat metabolic disease in terms of causal factors leading to success and failure in this endeavour. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is exemplified by the estimate of >99% of projects initiated in preclinical industrial labs failing to deliver newmedicines (Paul et al., 2010).”
BackgroundGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102
New genetic loci link adipose and insulin biology to body fat distribution
The ADIPOGen Consortium, Shungin, D., The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The GEFOS Consortium, The GENIE Consortium, The, G. L. G. C., The, I. C. B. P., The International Endogene Consortium, Study, T. L. C., et al. (2015) · Nature · doi:10.1038/nature14132 · Cited by 1,580
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484 · cited 2×
“Adiposity raises intracellular lipid content and intermediate metabolites such as DAG, acetyl-CoA, and various ceramides, which are associated with the development of insulin resistance (Samuel and Shulman, 2016).”
BackgroundDiabetes: a 21st century challenge
Zimmet, P. Z., Magliano, D. J., Herman, W. H., & Shaw, J. E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70112-8 · Cited by 1,062
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 2×
“Pharmaceutical development of agonists targeting the GLP-1 receptor has largely focused on engineering strategies to prolong the pharmacokinetic properties of native GLP-1 or exendin-4, a potent GLP-1 receptor agonist isolated from the salivary gland of the Gila monster lizard (39 amino acids, 53% similarity with GLP-…”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Cited by
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Samms, R. J., Zhang, G., He, W., Ilkayeva, O., Droz, B. A., Bauer, S. M., Stutsman, C., Pirro, V., Collins, K. A., Furber, E. C., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101550 · Cited by 93
“The dramatic worldwide rise in the prevalence of obesity and type 2 diabetes (T2D) over the past 50 years [1,2], coupled with a lack of optimal therapeutics, has recently fueled the discovery and development of next generation diabetes medications [3,4].”
BackgroundSelf-citationSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Self-citationHou, T., Bian, Y., McGuire, T., & Xie, X.-Q. (2021) · Biomolecules · doi:10.3390/biom11060870 · Cited by 30
“However, an increasing number of drugs targeting the orthosteric sites have been withdrawn from the market due to low efficacy and undesired side effects [6,7].”
Background
Metadata
- Authors
- Sloop, K. W., Emmerson, P. J., Statnick, M. A., & Willard, F. S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-03-25
- Volume
- 175
- Issue
- 21
- Pages
- 4060-4071
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2794339592
- Cited by
- 51
- References
- 19
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The current state of GPCR‐based drug discovery to treat metabolic disease. https://app.cochat.ai/papers/10.1111/bph.14157
- The paper
- Sloop, K. W., Emmerson, P. J., Statnick, M. A., & Willard, F. S. (2018). The current state of GPCR‐based drug discovery to treat metabolic disease. British Journal of Pharmacology. https://doi.org/10.1111/bph.14157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.